Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Tetraphase antibiotic...

    Tetraphase antibiotic may reach up to $700 mln in annual sales: CEO

    Written by supriya kashyap kashyap Published On 2017-02-10T10:07:31+05:30  |  Updated On 10 Feb 2017 10:07 AM IST
    Tetraphase antibiotic may reach up to $700 mln in annual sales: CEO

    New York : Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.


    The antibiotic, eravacycline, is being studied in a pivotal 450-patient Phase III trial for intra-abdominal infections. Tetraphase expects to have the data in the fourth quarter after which it will apply for U.S. approval that could come in 2018.


    "The FDA has been very supportive of getting new antibiotics approved, so clearly we have a fast-track agreement with them once we get the positive data," Macdonald told Reuters.


    He said he believes eravacycline could garner annual sales that would take it at least halfway to block buster status.


    "If you have a successful gram negative drug like eravacycline, you're looking at somewhere in the $500-to-$700-million range. I think that's certainly reachable," Macdonald said.


    Eravacycline is a synthetic tetracycline derivative for drug-resistant bacterial infections administered intravenously in hospital.


    The company is also enrolling for a 1,000-patient eravacycline trial in complicated urinary tract infections.


    Tetraphase is developing the drug with the help of a $80 million grant from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. It currently has enough funding to take it through the second half of 2018, the CEO said.


    Antibiotic resistance and the emergence of so-called super bugs, caused by widespread antibiotic overuse and the ability of bacteria to evolve, is seen as a global health threat.


    The U.S. government has been very helpful in funding for new antibiotics, Macdonald said.


    In September, Medicines Co and Roche received significant funding from BARDA to help develop antibiotics.


    Many major drugmakers abandoned antibiotic development because they are not nearly as profitable as other medicines, such as cancer drugs, and marketing them aggressively would likely only exacerbate the overuse problem.


    Tetraphase expects to also apply for European approval late this year, and hopes to find a partner to sell the drug outside the United States.


    "We can do it in the U.S. on our own," Macdonald said.


    "For us to be able to provide the growth we need and keep our investor base happy, that's a much better business model to do it ourselves," he added. "If you want to commercialize it worldwide, we're not capable of doing that."


    The 75-employee company with a market value under $200 million will build a small sales force for eravacycline, Macdonald said.


    Tetraphase already has someone with commercial experience from Merck & Co and Cubist to oversee the eravacycline launch, once approved.


    "We just need the data," Macdonald said.

    antibioticbacterial infectionBARDABiomedical Advanced Research and Development AuthorityGuy Macdonaldintra-abdominal infectionMerckRocheTetraphaseurinary tract infection
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok